Increased Transglutaminase 2 Expression and Activity in Rodent Models of Obesity/Metabolic Syndrome and Aging

Diastolic dysfunction of the heart and decreased compliance of the vasculature and lungs (i.e., increased organ tissue stiffness) are known features of obesity and the metabolic syndrome. Similarly, cardiac diastolic dysfunction is associated with aging. Elevation of the enzyme transglutaminase 2 (TG2) leads to protein cross-linking and enhanced collagen synthesis and participates as a candidate pathway for development of tissue stiffness. With these observations in mind we hypothesized that TG2 may be elevated in tissues of a rat model of obesity/metabolic syndrome (the ZSF 1 rat) and a mouse model of aging, i.e., the senescent SAMP8 mouse. In the experiments reported here, TG2 expression and activity were found for the first time to be spontaneously elevated in organs from both the ZSF1 rat and the SAMP8 mouse. These observations are consistent with a hypothesis that a TG2-related pathway may participate in the known tissue stiffness associated with cardiac diastolic dysfunction in these two rodent models. The potential TG2 pathway needs better correlation with physiologic dysfunction and may eventually provide novel therapeutic insights to improve tissue compliance.

[1]  B. Fanburg,et al.  Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  K. Ha,et al.  The vicious cycle between transglutaminase 2 and reactive oxygen species in hyperglycemic memory–induced endothelial dysfunction , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  W. Paulus,et al.  Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. , 2019, Circulation. Heart failure.

[4]  J. Sowers,et al.  Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor , 2019, Hypertension.

[5]  G. Johnson,et al.  Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension , 2019, American journal of hypertension.

[6]  M. Gladwin,et al.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction , 2018, The Journal of physiology.

[7]  L. Santhanam,et al.  Knockdown of transglutaminase-2 prevents early age-induced vascular changes in mice1. , 2018, Acta cirurgica brasileira.

[8]  Soo-Youl Kim,et al.  New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds , 2018, Medical Science.

[9]  T. Finkel,et al.  The role of mitochondria in aging , 2018, The Journal of clinical investigation.

[10]  K. M. Choi,et al.  Aging and anatomical variations in lung tissue stiffness. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[11]  E. Bedrick,et al.  Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. , 2018, The American journal of medicine.

[12]  P. Camelliti,et al.  Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor , 2018, Cell Death & Disease.

[13]  Mario J. Garcia,et al.  Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. , 2018, Journal of molecular and cellular cardiology.

[14]  M. Rojas,et al.  Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics , 2018, Front. Med..

[15]  B. Fanburg,et al.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[16]  Danica Chen,et al.  The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop. , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.

[17]  R. Mrowka Arterial hypertension , 2017, Acta physiologica.

[18]  A. Choi,et al.  Glucose Transporter 1‐Dependent Glycolysis Is Increased during Aging‐Related Lung Fibrosis, and Phloretin Inhibits Lung Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[19]  C. Greenberg,et al.  Role of tissue transglutaminase-2 (TG2)-mediated aminylation in biological processes , 2017, Amino Acids.

[20]  A. Oberg,et al.  Cellular senescence mediates fibrotic pulmonary disease , 2017, Nature Communications.

[21]  M. Halushka,et al.  Tissue Transglutaminase Modulates Vascular Stiffness and Function Through Crosslinking‐Dependent and Crosslinking‐Independent Functions , 2017, Journal of the American Heart Association.

[22]  B. Levine,et al.  Role of tissue transglutaminase in age-associated ventricular stiffness , 2016, Amino Acids.

[23]  D. Grinnan,et al.  The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension , 2016, Journal of diabetes research.

[24]  F. Paneni,et al.  Ageing, metabolism and cardiovascular disease , 2016, The Journal of physiology.

[25]  W. Paulus,et al.  Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome , 2016, Circulation. Heart failure.

[26]  Zhaoyang Feng,et al.  Reprogramming of energy metabolism as a driver of aging , 2016, Oncotarget.

[27]  T. Gillebert,et al.  Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction. , 2015, American journal of physiology. Heart and circulatory physiology.

[28]  A. Leite-Moreira,et al.  Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. , 2015, American journal of physiology. Heart and circulatory physiology.

[29]  R. Mohney,et al.  Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. , 2015, Journal of proteome research.

[30]  N. Muma,et al.  Serotonylation and Transamidation of Other Monoamines. , 2015, ACS chemical neuroscience.

[31]  J. Harral,et al.  Obesity-Related Pulmonary Arterial Hypertension in Rats Correlates with Increased Circulating Inflammatory Cytokines and Lipids and with Oxidant Damage in the Arterial Wall but not with Hypoxia , 2014, Pulmonary circulation.

[32]  S. Comhair,et al.  Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[33]  N. Frangogiannis,et al.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. , 2014, Translational research : the journal of laboratory and clinical medicine.

[34]  Richard T. Lee,et al.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. , 2014, Circulation research.

[35]  Thomas H Thatcher,et al.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. , 2014, American journal of respiratory cell and molecular biology.

[36]  M. Halushka,et al.  Exercise, Vascular Stiffness, and Tissue Transglutaminase , 2014, Journal of the American Heart Association.

[37]  K. Penumatsa,et al.  Transglutaminase 2-mediated serotonylation in pulmonary hypertension. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[38]  B. Fanburg,et al.  Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice. , 2014, ACS chemical biology.

[39]  M. Kieliszek,et al.  Microbial transglutaminase and its application in the food industry. A review , 2013, Folia Microbiologica.

[40]  W. Paulus,et al.  Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model , 2013, Circulation. Heart failure.

[41]  K. Mehta,et al.  Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway , 2012, PloS one.

[42]  James Strait,et al.  Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease , 2012, Heart Failure Reviews.

[43]  M. Sekiguchi,et al.  Age-dependent increases in the oxidative damage of DNA, RNA, and their metabolites in normal and senescence-accelerated mice analyzed by LC-MS/MS: urinary 8-oxoguanosine as a novel biomarker of aging. , 2012, Free radical biology & medicine.

[44]  E. Goldsmith,et al.  Diabetes-Induced Alterations in the Extracellular Matrix and Their Impact on Myocardial Function , 2012, Microscopy and Microanalysis.

[45]  Pruthvi N. Shetty,et al.  Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function , 2011, Journal of cardiovascular disease research.

[46]  D. Sorescu,et al.  Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. , 2011, American journal of physiology. Heart and circulatory physiology.

[47]  G. Escames,et al.  Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[48]  Yingling Liu,et al.  Role of protein transamidation in serotonin-induced proliferation and migration of pulmonary artery smooth muscle cells. , 2011, American journal of respiratory cell and molecular biology.

[49]  N. Frangogiannis,et al.  Aging and Cardiac Fibrosis. , 2011, Aging and disease.

[50]  T. Ørntoft,et al.  Pressure Load: The Main Factor for Altered Gene Expression in Right Ventricular Hypertrophy in Chronic Hypoxic Rats , 2011, PloS one.

[51]  J. Juliard [Heart failure in the elderly]. , 2009, La Revue du praticien.

[52]  Michael Bader,et al.  Intracellular Serotonin Modulates Insulin Secretion from Pancreatic β-Cells by Protein Serotonylation , 2009, PLoS biology.

[53]  S. Twigg,et al.  Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers , 2008, Vascular health and risk management.

[54]  M. Picken,et al.  Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. , 2007, American journal of physiology. Renal physiology.

[55]  Adrian Pistea,et al.  Flow-Dependent Remodeling of Small Arteries in Mice Deficient for Tissue-Type Transglutaminase: Possible Compensation by Macrophage-Derived Factor XIII , 2006, Circulation research.

[56]  L. Ferrucci,et al.  Interleukin-6 in aging and chronic disease: a magnificent pathway. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[57]  F. Villarreal,et al.  The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[58]  Michael C. Wendl,et al.  Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.

[59]  Linghong Huang,et al.  Inhibition of Transglutaminase Activity Reduces Extracellular Matrix Accumulation Induced by High Glucose Levels in Proximal Tubular Epithelial Cells* , 2004, Journal of Biological Chemistry.

[60]  D. Kass,et al.  What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? , 2004, Circulation research.

[61]  D. Vorp,et al.  Crosslinking of collagen gels by transglutaminase. , 2004, Journal of biomedical materials research. Part A.

[62]  J. Piccini,et al.  New insights into diastolic heart failure: role of diabetes mellitus. , 2004, The American journal of medicine.

[63]  Rita Casadio,et al.  Transglutaminases: nature's biological glues. , 2002, The Biochemical journal.

[64]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[65]  G. Dorn,et al.  Cardiac Specific Overexpression of Transglutaminase II (Gh) Results in a Unique Hypertrophy Phenotype Independent of Phospholipase C Activation* , 1999, The Journal of Biological Chemistry.

[66]  T. Kurokawa,et al.  Difference between senescence-accelerated prone and resistant mice in response to insulin in the heart , 1998, Mechanisms of Ageing and Development.

[67]  K. Kashima,et al.  Immunohistochemical study on tissue transglutaminase and copper-zinc superoxide dismutase in human myocardium: Its relevance to apoptosis detected by the nick end labelling method , 1997, Virchows Archiv.

[68]  R. Rice,et al.  Transglutaminases: multifunctional cross‐linking enzymes that stabilize tissues , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  P. Blanchette,et al.  Diastolic dysfunction in elderly patients with congestive heart failure. , 1989, The American journal of cardiology.

[70]  D. Mosher,et al.  Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. , 1979, The Journal of clinical investigation.

[71]  K. Brown Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype , 2012, Breast Cancer Research and Treatment.

[72]  Edward G Lakatta,et al.  Aging-associated cardiovascular changes and their relationship to heart failure. , 2012, Heart failure clinics.